Niagen. BIOSCIENCE

NEWS RELEASE

ChromaDex Announces Top-line Results of its Second Human Clinical Trial

2017-09-26

- The Study Establishes an Effective Dose Range and Validates Safety for NIAGEN® Nicotinamide Riboside Chloride in 140 Humans Over an 8-week Period -

IRVINE, Calif., Sept. 26, 2017 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of science-based, proprietary health and wellness consumer products and ingredient technologies that promote health longevity, announced today that the initial results of its second human clinical study of NIAGEN® nicotinamide riboside chloride (NR) have confirmed NR significantly and sustainably raises the co-enzyme nicotinamide adenine dinucleotide (NAD+) in 140 healthy human volunteers over 8-weeks.

In this study, participants in the active group received 100, 300, or 1000mg per day. Results from the randomized, double-blind, placebo controlled, parallel-arm trial demonstrated that NR produced statistically significant increases in blood NAD+ compared to placebo that were related to the dose of NR consumed, demonstrating a dose response. Levels remained elevated throughout the duration of the study, thereby establishing an efficacious range for daily consumption. The study confirms not only efficacy in raising NAD+, but also definitively documents the safety of daily use of NR.

Frank Jaksch Jr., founder and CEO of ChromaDex, commented, "This study is a pivotal milestone in the clinical science of NIAGEN® and is key to better understanding its role in human health. For the first time, we have established an effective dose range for long term use in humans. This paves the way for important clinical work in the modulation of aging, as well as in other health-related categories."

Maintenance of sufficient levels of NAD+ is key to cellular energy metabolism and mitochondrial function. Cellular energy not only fuels our most basic bodily functions, it is also necessary to defend against oxidative stress in the

body, repair DNA damage, and create the building blocks for DNA and RNA. In humans and animals, NAD+ levels decrease in normal aging. This observation has led to dozens of published preclinical studies demonstrating the efficacy of NIAGEN® in raising NAD+, as well as some of the potential mechanisms by which NIAGEN® can help reduce the metabolic stresses of normal aging.

Study publication in peer review literature will be critically important for supporting future University and NIH-Sponsored clinical efficacy trials. The full results of the study will be submitted for publication in a peer review journal shortly.

For more information on ChromaDex, visit: **https://www.chromadex.com/**.

About ChromaDex:
ChromaDex leverages its complementary business units to discover, acquire, develop and commercialize patented and proprietary health and wellness consumer products and ingredient technologies that promote healthy longevity. In addition to our consumer product and ingredient technologies units, we also have business units focused on natural product fine chemicals (known as "phytochemicals"), and product regulatory and safety consulting. As a result of our relationships with leading universities and research institutions, we are able to discover and license early stage, IP-backed ingredient technologies. We then utilize our in-house chemistry, regulatory and safety consulting business units to develop commercially viable ingredients. Our consumer product and ingredient portfolio are backed with clinical and scientific research, as well as extensive IP protection. Our portfolio of patented ingredient technologies includes **NIAGEN®** nicotinamide riboside; **pTeroPure®** pterostilbene; **PURENERGY®**, a caffeine-pTeroPure® co-crystal; **IMMULINA™**, a spirulina extract; and **AnthOrigin®,** anthocyanins derived from a domestically-produced, water-extracted purple corn husk. To learn more about ChromaDex, please visit **www.ChromaDex.com**.

Forward-Looking Statements:
This release contains forward-looking statements relating to ChromaDex and ChromaDex's business within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, including statements related to results of the NIAGEN® study and its significance, the importance of maintaining sufficient levels of NAD+ and it being the key to cellular energy metabolism and mitochondrial function. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects", "anticipates", "intends", "estimates", "plans", "potential", "possible", "probable", "believes", "seeks", "may", "will", "should", "could" or the negative of such terms or other similar expressions. More detailed information about ChromaDex and the risk factors that may affect the realization of forward-looking statements is set forth in ChromaDex's Annual Report on Form 10-K for the fiscal year ended December 31, 2016, ChromaDex's Quarterly Reports on Form 10-Q and

other filings submitted by ChromaDex to the SEC, copies of which may be obtained from the SEC's website at **www.sec.gov**. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and actual results may differ materially from those suggested by these forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement and ChromaDex undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.

ChromaDex Investor Relations Contact:
Andrew Johnson, Director of Investor Relations
949-419-0288
andrewj@chromadex.com

ChromaDex Public Relations Contact:
Breah Ostendorf, Director of Marketing
949-537-4103
breaho@chromadex.com

ChromaDex, Inc.